Back to top
more

ACADIA Pharmaceuticals (ACAD)

(Real Time Quote from BATS)

$18.50 USD

18.50
191,113

+0.84 (4.76%)

Updated Nov 11, 2024 10:44 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

ACADIA's (ACAD) Q1 Earnings & Revenues Fall Shy of Estimates

by Zacks Equity Research

ACADIA's (ACAD) earnings and sales lag estimates in the first quarter of 2020. The company trims its 2020 revenue guidance due to the coronavirus impact. Stock declines in after-hours trading.

Acadia Pharmaceuticals (ACAD) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Acadia (ACAD) delivered earnings and revenue surprises of -23.91% and -3.36%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Lineage Cell (LCTX) to Post Q1 Earnings: What's in the Cards?

by Zacks Equity Research

On Lineage Cell's (LCTX) Q1 earnings call, investor focus will be on its progress with the pipeline candidate OpRegen, currently being developed for treating dry AMD, as well as other pipeline updates.

Kinjel Shah headshot

5 Drug/Biotech Stocks Set to Outpace Q1 Earnings Estimates

by Kinjel Shah

Let us take a look at some drug/biotech stocks that are poised to beat on first-quarter earnings.

BorgWarner (BWA) to Post Q1 Earnings: What's in the Offing?

by Zacks Equity Research

Heightening coronavirus fears, along with supply-chain inefficiencies and higher research and development costs, are likely to have clipped BorgWarner's (BWA) margins in Q1.

Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Is Acadia (ACAD) Up 1.1% Since Last Earnings Report?

by Zacks Equity Research

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ACADIA (ACAD) Q4 Earnings Surpass, Nuplazid Drives Sales

by Zacks Equity Research

ACADIA (ACAD) beats on earnings and revenues in the fourth quarter.

Acadia Pharmaceuticals (ACAD) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Acadia (ACAD) delivered earnings and revenue surprises of 8.11% and 2.57%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

ACADIA (ACAD) Up More Than 100% in the Past Year: Here's Why

by Zacks Equity Research

ACADIA's (ACAD) only marketed drug Nuplazid registers strong sales in 2019. The drug's label expansion efforts also look promising with several studies currently underway for various CNS disorders.

Has ACADIA Pharmaceuticals (ACAD) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (ACAD) Outperforming Other Medical Stocks This Year?

Ekta Bagri headshot

Biotech Stock Outlook: M&A Activity Retains Growth Streak

by Ekta Bagri

The biotech sector enjoys a good run in 2019 on the back of the M&A activities and positive pipeline updates underway. We expect this momentum to stay in 2020 as well.

Ekta Bagri headshot

5 Biotech Stocks That Have More Than Doubled This Year

by Ekta Bagri

The biotech sector has had a good run in 2019 on the back of ongoing M&A activities and positive pipeline updates.

The Zacks Analyst Blog Highlights: ACADIA, Compugen, Cue Biopharma, Epizyme and Krystal Biotech

by Zacks Equity Research

The Zacks Analyst Blog Highlights: ACADIA, Compugen, Cue Biopharma, Epizyme and Krystal Biotech

Indrajit Bandyopadhyay headshot

5 Biotech Stocks Up More Than 100% This Year So Far

by Indrajit Bandyopadhyay

The biotech sector recovers on the back of rising M&A activities and pipeline successes in 2019 after a dismal 2018. Here we discuss five biotech companies recording impressive growth.

What Makes Acadia Pharmaceuticals (ACAD) a Strong Momentum Stock: Buy Now?

by Zacks Equity Research

Does Acadia Pharmaceuticals (ACAD) have what it takes to be a top stock pick for momentum investors? Let's find out.

Top Ranked Momentum Stocks to Buy for November 25th

by Zacks Equity Research

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, November 25th.

Medtronic (MDT) to Report Q2 Earnings: What's in Store?

by Zacks Equity Research

In the fiscal second quarter, Medtronic (MDT) is expected to have registered strong growth in its ICD and CRT product lines.

The Zacks Analyst Blog Highlights: Coherus, Incyte, ACADIA and Celgene

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Coherus, Incyte, ACADIA and Celgene

4 Biotech Stocks That Could Keep Beating Wall Street

by Zacks Equity Research

The biotechnology industry has lagged the broader market so far this year, but these four stocks have done pretty well and should continue to do so.

What Makes Acadia Pharmaceuticals (ACAD) a Strong Momentum Stock: Buy Now?

by Zacks Equity Research

Does Acadia Pharmaceuticals (ACAD) have what it takes to be a top stock pick for momentum investors? Let's find out.

Acadia (ACAD) Upgraded to Buy: Here's Why

by Zacks Equity Research

Acadia (ACAD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Acadia Pharmaceuticals (ACAD) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Acadia (ACAD) delivered earnings and revenue surprises of 29.27% and 6.79%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Cigna (CI) to Report Q3 Earnings: What's in the Offing?

by Zacks Equity Research

Cigna (CI) Q3 earnings are likely to have benefited from higher contribution across all its segments and effect of share buyback.

Teladoc (TDOC) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Teladoc (TDOC) Q3 earning are likely to have benefited from increased membership and visits, and accretive effect of earlier acquisitions.